Lgl Partners, LLC Biogen Inc. Transaction History

Lgl Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $67,401 - $81,894	-267 Reduced 23.48%	870 $240,000
Q3 2022 Nov 09, 2022	SELL	$194.69 - $268.46 $5,061 - $6,979	-26 Reduced 2.24%	1,137 $304,000
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $2,131 - $2,685	-11 Reduced 0.94%	1,163 $245,000
Q2 2021 Aug 09, 2021	SELL	$259.0 - $414.71 $31,080 - $49,765	-120 Reduced 9.27%	1,174 $407,000
Q2 2020 Aug 10, 2020	SELL	$258.66 - $342.55 $34,660 - $45,901	-134 Reduced 9.38%	1,294 $346,000
Q1 2020 May 13, 2020	BUY	$268.85 - $341.04 $10,754 - $13,641	40 Added 2.88%	1,428 $452,000
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $46,749 - $52,434	215 Added 18.33%	1,388 $323,000
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $10,964 - $12,086	50 Added 4.45%	1,173 $274,000
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $243,365 - $380,652	1,123 New	1,123 $265,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Lgl Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Lgl Partners, LLC with notifications on news.